GPC-100

A Phase 2, Randomized, Open-Label Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

  • Myeloma Service

What's the purpose of the trial?

This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration.

Trial status

Accepting patients

Phase
Phase 2
Enrollment
40
Last Updated
2 months ago
Patient Screener

Participating Centers

There are 10 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • GPC-100
  • Granulocyte Colony-Stimulating Factor is a glycoprotein used to stimulate the bone marrow to help with granulocyte and stem cell production.
  • Propranolol is a kind of medication called a beta blocker that is used to treat several different cardiovascular conditions.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

GPC-100 + Propranolol

Accepting patients

GPC-100 + Propranolol + Granulocyte Colony-Stimulating Factor (GCSF)

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.